NCT04837768

Brief Summary

The aim of this study is to investigate whether intramuscular progesterone supplementation will improve clinical pregnancy rates and ongoing pregnancy rates in patients with decreased serum progesterone levels on the day of embryo transfer in artificial frozen cycles.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
354

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2021

Shorter than P25 for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 6, 2021

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 8, 2021

Completed
4 months until next milestone

Study Start

First participant enrolled

July 27, 2021

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2022

Completed
14 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 15, 2022

Completed
Last Updated

March 17, 2022

Status Verified

March 1, 2022

Enrollment Period

7 months

First QC Date

April 6, 2021

Last Update Submit

March 15, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Clinical pregnancy rates

    Detected via ultrasound

    4 weeks after the day of embryo transfer

Secondary Outcomes (1)

  • Ongoing pregnancy rates

    12 weeks after the day of embryo transfer

Study Arms (2)

Serum Progesterone Levels >9.2 ng/ml

ACTIVE COMPARATOR

These patients will receive only twice-daily vaginal progesterone supplementation following embryo transfer

Drug: Twice-daily transvaginal progesterone supplementation

Serum Progesterone Levels <9.2 ng/ml

ACTIVE COMPARATOR

These patients will receive twice-weekly intramuscular progesterone supplementation in addition to the twice-daily vaginal supplementation following embryo transfer

Drug: Twice-weekly intramuscular + Twice-daily transvaginal progesterone supplementation

Interventions

Patients with serum progesterone levels \>9.2 ng/ml on the day of embryo transfer in artificial frozen cycles will receive the traditional twice-daily vaginal progesterone supplementation till 12 weeks gestation.

Serum Progesterone Levels >9.2 ng/ml

Patients with serum progesterone levels \<9.2 ng/ml on the day of embryo transfer in artificial frozen cycles will receive the twice-daily vaginal progesterone in addition to twice-weekly intramuscular progesterone supplementation till 12 weeks gestation.

Serum Progesterone Levels <9.2 ng/ml

Eligibility Criteria

Age20 Years - 40 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age range 20-40 years
  • BMI \< 40 kg/m2
  • Endometrial thickness \>7mm
  • Double embryo transfer (Day 5), Grade 1 or 2.

You may not qualify if:

  • Autoimmune diseases
  • Uncontrolled medical conditions
  • Recurrent implantation failure
  • Anatomical uterine abnormalities as polyps, fibroids or Müllerian anomalies.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Cairo University, Faculty of Medicine, Department of Obstetrics and Gynecology

Cairo, 11956, Egypt

Location

AlBoshra IVF & Infertility Treatment Centre

Cairo, 12611, Egypt

Location

Related Publications (7)

  • Labarta E, Mariani G, Holtmann N, Celada P, Remohi J, Bosch E. Low serum progesterone on the day of embryo transfer is associated with a diminished ongoing pregnancy rate in oocyte donation cycles after artificial endometrial preparation: a prospective study. Hum Reprod. 2017 Dec 1;32(12):2437-2442. doi: 10.1093/humrep/dex316.

    PMID: 29040638BACKGROUND
  • Boynukalin FK, Gultomruk M, Turgut E, Demir B, Findikli N, Serdarogullari M, Coban O, Yarkiner Z, Bahceci M. Measuring the serum progesterone level on the day of transfer can be an additional tool to maximize ongoing pregnancies in single euploid frozen blastocyst transfers. Reprod Biol Endocrinol. 2019 Nov 29;17(1):102. doi: 10.1186/s12958-019-0549-9.

    PMID: 31783865BACKGROUND
  • Kofinas JD, Blakemore J, McCulloh DH, Grifo J. Serum progesterone levels greater than 20 ng/dl on day of embryo transfer are associated with lower live birth and higher pregnancy loss rates. J Assist Reprod Genet. 2015 Sep;32(9):1395-9. doi: 10.1007/s10815-015-0546-7. Epub 2015 Aug 4.

    PMID: 26238390BACKGROUND
  • Yovich JL, Conceicao JL, Stanger JD, Hinchliffe PM, Keane KN. Mid-luteal serum progesterone concentrations govern implantation rates for cryopreserved embryo transfers conducted under hormone replacement. Reprod Biomed Online. 2015 Aug;31(2):180-91. doi: 10.1016/j.rbmo.2015.05.005. Epub 2015 May 18.

    PMID: 26099447BACKGROUND
  • Mackens S, Santos-Ribeiro S, van de Vijver A, Racca A, Van Landuyt L, Tournaye H, Blockeel C. Frozen embryo transfer: a review on the optimal endometrial preparation and timing. Hum Reprod. 2017 Nov 1;32(11):2234-2242. doi: 10.1093/humrep/dex285.

    PMID: 29025055BACKGROUND
  • Shapiro DB, Pappadakis JA, Ellsworth NM, Hait HI, Nagy ZP. Progesterone replacement with vaginal gel versus i.m. injection: cycle and pregnancy outcomes in IVF patients receiving vitrified blastocysts. Hum Reprod. 2014 Aug;29(8):1706-11. doi: 10.1093/humrep/deu121. Epub 2014 May 20.

    PMID: 24847018BACKGROUND
  • Paulson RJ, Collins MG, Yankov VI. Progesterone pharmacokinetics and pharmacodynamics with 3 dosages and 2 regimens of an effervescent micronized progesterone vaginal insert. J Clin Endocrinol Metab. 2014 Nov;99(11):4241-9. doi: 10.1210/jc.2013-3937. Epub 2014 Feb 25.

    PMID: 24606090BACKGROUND

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: Patients undergoing frozen cycles following ICSI will receive artificial endometrial preparation from day 2/3 of their cycle in the form of 2mg Estradiol Valerate pills thrice daily for 7-10 days. After confirming endometrial thickness \> 7mm via TVS, progesterone supplementation will start via Prontogest® 400mg vaginal pessaries twice daily for 5 days, ending with the day of embryo transfer (ET). On the morning of ET, serum progesterone will be measured and if the value is over 9.2ng/ml, only the traditional twice daily vaginal progesterone will be resumed until 12 weeks gestation. If the value is under 9.2 ng/ml, intramuscular progesterone supplementation with Prontogest® 100mg will be added in twice-weekly doses (every 3 days) to the vaginal supplementation. Quantitative β-hcg 2 weeks after ET to detect chemical pregnancies. Ultrasound 4 weeks after ET to detect clinical pregnancies. Ultrasound repeated at 12 weeks to confirm ongoing pregnancy rates.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Lecturer in the Department of Obstetrics and Gynecology

Study Record Dates

First Submitted

April 6, 2021

First Posted

April 8, 2021

Study Start

July 27, 2021

Primary Completion

March 1, 2022

Study Completion

March 15, 2022

Last Updated

March 17, 2022

Record last verified: 2022-03

Locations